Compare Stocks

→ Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHSI Guardion Health Sciences	$9.69 +1.7%	$8.49	$5.01 ▼ $10.75	$12.44M	0.9	132,042 shs	6,608 shs
ICOTF iCo Therapeutics	$0.38	$0.37	$0.80 ▼ $1.82	$3.42M	2.03	4,760 shs	N/A
MTFB MOTIF BIO PLC/S	$0.11	$0.10	$0.08 ▼ $11.50	N/A	N/A	N/A	867,698 shs
NVUS Novus Therapeutics	$2.80 +1.8%	$13.23	$4.50 ▼ $27.32	$4.02M	2.07	78,851 shs	142,914 shs
RTTR Ritter Pharmaceuticals	$0.28 +3.7%	$2.99	$0.15 ▼ $1.27	$12.92M	-0.43	14.23 million shs	1.17 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHSI Guardion Health Sciences	+1.68%	+4.76%	+21.13%	+20.37%	+60.43%
ICOTF iCo Therapeutics	0.00%	+16.15%	+18.00%	-27.97%	-12.19%
MTFB MOTIF BIO PLC/S	0.00%	0.00%	0.00%	0.00%	0.00%
NVUS Novus Therapeutics	+1.82%	-0.71%	+16.18%	+70.73%	+45.08%
RTTR Ritter Pharmaceuticals	+3.67%	-8.23%	-7.01%	-33.04%	-72.74%

Nvidia’s Quiet $1 Trillion Pivot (Ad)

Nvidia recently added $277 billion in market cap … IN ONE DAY.

Find out details on these three critical Nvidia partners immediately.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHSI Guardion Health Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHSI Guardion Health Sciences	2.00	Hold	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHSI Guardion Health Sciences	$12.06M	1.03	$0.14 per share	68.50	$6.39 per share	1.52
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	$13.13 per share	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	$0.10 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHSI Guardion Health Sciences	$160K	-$4.02	N/A	∞	N/A	-16.69%	-77.29%	-42.08%	8/12/2024 (Estimated)
ICOTF iCo Therapeutics	-$1.11M	-$0.40	N/A	∞	N/A	N/A	N/A	-288.85%	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	-$16.01M	-$21.58	N/A	N/A	N/A	N/A	-133.49%	-30.52%	N/A
RTTR Ritter Pharmaceuticals	-$10.13M	N/A	N/A	∞	N/A	N/A	N/A	-162.05%	N/A

Latest ICOTF, NVUS, GHSI, RTTR, and MTFB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2024	Q1 2024	GHSI Guardion Health Sciences	N/A	-$3.71	-$3.71	-$3.71	N/A	$3.00 million
3/28/2024	Q4 2023	GHSI Guardion Health Sciences	N/A	$0.33	+$0.33	$0.33	N/A	$21.56 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHSI Guardion Health Sciences	N/A	N/A	N/A	N/A	N/A
ICOTF iCo Therapeutics	N/A	N/A	N/A	N/A	N/A
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	N/A	N/A	N/A	N/A
RTTR Ritter Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHSI Guardion Health Sciences	N/A	8.17	6.49
ICOTF iCo Therapeutics	N/A	0.72	0.72
MTFB MOTIF BIO PLC/S	N/A	N/A	N/A
NVUS Novus Therapeutics	N/A	18.78	18.78
RTTR Ritter Pharmaceuticals	N/A	3.67	3.67

Ownership

Institutional Ownership

Company	Institutional Ownership
GHSI Guardion Health Sciences	20.21%
ICOTF iCo Therapeutics	N/A
MTFB MOTIF BIO PLC/S	N/A
NVUS Novus Therapeutics	N/A
RTTR Ritter Pharmaceuticals	0.84%

Insider Ownership

Company	Insider Ownership
GHSI Guardion Health Sciences	1.32%
ICOTF iCo Therapeutics	N/A
MTFB MOTIF BIO PLC/S	N/A
NVUS Novus Therapeutics	2.20%
RTTR Ritter Pharmaceuticals	15.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
GHSI Guardion Health Sciences	9	1.28 million	1.27 million	Not Optionable
ICOTF iCo Therapeutics	N/A	9.05 million	N/A	Not Optionable
MTFB MOTIF BIO PLC/S	7	N/A	N/A	Not Optionable
NVUS Novus Therapeutics	7	1.44 million	N/A	Not Optionable
RTTR Ritter Pharmaceuticals	7	46.15 million	N/A	Not Optionable

ICOTF, NVUS, GHSI, RTTR, and MTFB Headlines

Recent News About These Companies

May 22, 2024 | tribute.ca

John Ritter Biography & Movies

April 19, 2024 | si.com

Jeff Ritter

January 24, 2024 | health.usnews.com

Dr. John D. Ritter

October 28, 2023 | politico.eu

German chocolate war ends with Ritter Sport victory

September 15, 2023 | health.usnews.com

Kristen Ritter

July 8, 2023 | dailygazette.com

Op-ed column: Sandusky sex charges contrast with setup against Scott Ritter

July 8, 2023 | dailygazette.com

Scott Ritter arrested in Pennsylvania on child sex charges

July 8, 2023 | health.usnews.com

Dr. Harold K. Ritter

July 1, 2023 | bizjournals.com

Denver Business Journal welcomes new tech reporter

June 16, 2023 | slu.edu

Gary W. Ritter, Ph.D.

April 10, 2023 | usatoday.com

Jason Ritter and Drew Barrymore's raw conversation on her show may matter more than you think

March 29, 2023 | thestreet.com

Ritter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment

March 18, 2023 | finance.yahoo.com

Global Microbiome Market Report 2023: Major Players Include MicroBiome Therapeutics, Seres Therapeutics, Enterome Bioscience and Second Genome

January 19, 2023 | yahoo.com

Melanie Lynskey's husband Jason Ritter will join her in Yellowjackets this season

January 15, 2023 | morningjournal.com

Ritter Public Library in Vermilion adds book club

November 16, 2022 | finance.yahoo.com

Microbiome Clinical Trial Pipeline Space Brims with Novel Emerging Therapies with 130+ Key Players Working in the Domain | DelveInsight

October 1, 2022 | thehawkeye.com

Burlington freshman Olivia Ritter hits to pool as Olivia Kraus climbs out of the water

September 11, 2022 | cantonrep.com

Tuesday roundup: Sandy Valley senior golfer Connor Ritter records hole-in-one and sets new school record

Media Sentiment Over Time

Company Descriptions

Guardion Health Sciences

NASDAQ:GHSI

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

iCo Therapeutics

OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

MOTIF BIO PLC/S

NASDAQ:MTFB

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Novus Therapeutics

NASDAQ:NVUS

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Ritter Pharmaceuticals

NASDAQ:RTTR

Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial